{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:19:43Z","timestamp":1790662783358,"version":"4.1.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) are first-line antihypertensive drugs for many patients, and influencing angiotensin systems may play a role in dementia risk. This study aimed to investigate whether exposure to different antihypertensive drug classes compared with ACEI affects the risk of dementia and pathological dementia subtypes in a large multinational database study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a multinational population-based cohort study using electronic health databases in Hong Kong, the UK, Sweden and Australia. A common protocol was used to harmonise the study design. An active comparator, a new user design, was applied to compare the risk of all-cause dementia between different antihypertensive drug classes, with secondary outcomes of Alzheimer\u2019s disease (AD) and vascular dementia (VaD). Adjusted Cox proportional hazards models with inverse probability of treatment weighting were used to generate results in each study site and were pooled in meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One million nine hundred twenty-five thousand, five hundred sixty-three individuals were included across the four databases with a median follow-up ranging from 5.6 to 8.4\u00a0years. Compared to ACEI, initiation with ARB was associated with a reduced risk of incident all-cause dementia [hazard ratio (HR): 0.92, 95% confidence interval (CI): 0.89\u20130.94] and VaD (HR 0.87, 95% CI 0.78\u20130.96) but not AD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the largest multinational cohort study conducted to date investigating different classes of antihypertensive drugs and the risk of incident dementia. When initiating antihypertensives, physicians and patients should consider the reduced risk of all-cause dementia and VaD with ARB compared with ACEI in their risk\u2013benefit assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ageing\/afaf121","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T07:38:15Z","timestamp":1745825895000},"source":"Crossref","is-referenced-by-count":14,"title":["Antihypertensive drug classes and risk of incident dementia: a multinational population-based cohort study"],"prefix":"10.1093","volume":"54","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4117-4504","authenticated-orcid":false,"given":"Edmund C L","family":"Cheung","sequence":"first","affiliation":[{"name":"Centre for Safe Medication Practice and Research , Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2058-4096","authenticated-orcid":false,"given":"Matthew","family":"Adesuyan","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy , UCL School of Pharmacy, London,","place":["UK"]},{"name":"Centre for Medicines Optimisation Research and Education , University College London Hospitals NHS Foundation Trust, London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9291-0559","authenticated-orcid":false,"given":"M\u00e1t\u00e9","family":"Szilcz","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics , Karolinska Institutet, Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5063-6128","authenticated-orcid":false,"given":"Lisa M","family":"Kalisch Ellett","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre , Clinical and Health Sciences, University of South Australia, Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Shah","sequence":"additional","affiliation":[{"name":"Institute for Molecular Bioscience , The University of Queensland, Brisbane, QLD,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-5429","authenticated-orcid":false,"given":"Yogini H","family":"Jani","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy , UCL School of Pharmacy, London,","place":["UK"]},{"name":"Centre for Medicines Optimisation Research and Education , University College London Hospitals NHS Foundation Trust, London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"H\u00e4gg","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics , Karolinska Institutet, Stockholm,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Pratt","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre , Clinical and Health Sciences, University of South Australia, Adelaide, SA,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui Kai","family":"Lau","sequence":"additional","affiliation":[{"name":"Department of Medicine , School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Luo","sequence":"additional","affiliation":[{"name":"School of Public Health Sciences , University of Waterloo, Waterloo, Ontario,","place":["Canada"]},{"name":"Department of Social Work and Social Administration , The University of Hong Kong, Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6275-1147","authenticated-orcid":false,"given":"Eric Yuk Fai","family":"Wan","sequence":"additional","affiliation":[{"name":"Centre for Safe Medication Practice and Research , Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]},{"name":"Department of Family Medicine and Primary Care , School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]},{"name":"Advance Data Analytics for Medical Science (ADAMS) Limited , Hong Kong SAR,","place":["China"]},{"name":"The Institute of Cardiovascular Science and Medicine , Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther Wai Yin","family":"Chan","sequence":"additional","affiliation":[{"name":"Centre for Safe Medication Practice and Research , Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8242-0014","authenticated-orcid":false,"given":"Ian C K","family":"Wong","sequence":"additional","affiliation":[{"name":"Centre for Safe Medication Practice and Research , Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]},{"name":"Aston Pharmacy School , Aston University, Birmingham,","place":["UK"]},{"name":"School of Pharmacy , Medical Sciences Division, Macau University of Science and Technology, Taipa, Macau"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline K","family":"Yuen","sequence":"additional","affiliation":[{"name":"Department of Medicine , School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]},{"name":"School of Public Health , Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2145-3108","authenticated-orcid":false,"given":"Kai-Hang","family":"Yiu","sequence":"additional","affiliation":[{"name":"Department of Medicine , School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Howard","sequence":"additional","affiliation":[{"name":"Division of Psychiatry , University College London, London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Brauer","sequence":"additional","affiliation":[{"name":"Research Department of Practice and Policy , UCL School of Pharmacy, London,","place":["UK"]},{"name":"Centre for Medicines Optimisation Research and Education , University College London Hospitals NHS Foundation Trust, London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1513-8726","authenticated-orcid":false,"given":"Celine S L","family":"Chui","sequence":"additional","affiliation":[{"name":"Advance Data Analytics for Medical Science (ADAMS) Limited , Hong Kong SAR,","place":["China"]},{"name":"School of Public Health , Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]},{"name":"School of Nursing , Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,25]]},"reference":[{"key":"2025052516462920200_ref1","volume-title":"Dementia Key Facts 2020","author":"World Health Organization"},{"key":"2025052516462920200_ref2","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/S0140-6736(20)30367-6","article-title":"Dementia prevention, intervention, and care: 2020 report of the lancet commission","volume":"396","author":"Livingston","year":"2020","journal-title":"Lancet (London, England)"},{"key":"2025052516462920200_ref3","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/oxfordjournals.aje.a116868","article-title":"Untreated blood pressure level is inversely related to cognitive functioning: The Framingham study","volume":"138","author":"Elias","year":"1993","journal-title":"Am J Epidemiol"},{"key":"2025052516462920200_ref4","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1001\/jamaneurol.2014.1646","article-title":"Midlife hypertension and 20-year cognitive change: The atherosclerosis risk in communities neurocognitive study","volume":"71","author":"Gottesman","year":"2014","journal-title":"JAMA Neurol"},{"key":"2025052516462920200_ref5","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1001\/jama.2019.10575","article-title":"Association of Midlife to late-life blood pressure patterns with incident dementia","volume":"322","author":"Walker","year":"2019","journal-title":"JAMA"},{"key":"2025052516462920200_ref6","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/S1875-2136(08)71801-1","article-title":"Hypertension, cognitive decline and dementia","volume":"101","author":"Duron","year":"2008","journal-title":"Arch Cardiovasc Dis"},{"key":"2025052516462920200_ref7","doi-asserted-by":"publisher","first-page":"2046","DOI":"10.1001\/archinte.162.18.2046","article-title":"The prevention of dementia with antihypertensive treatment: New evidence from the systolic hypertension in Europe (Syst-Eur) study","volume":"162","author":"Forette","year":"2002","journal-title":"Arch Intern Med"},{"key":"2025052516462920200_ref8","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1001\/archneur.63.5.noc60013","article-title":"Antihypertensive medication use and incident Alzheimer disease: The Cache County study","volume":"63","author":"Khachaturian","year":"2006","journal-title":"Arch Neurol"},{"key":"2025052516462920200_ref9","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1001\/archinte.163.9.1069","article-title":"Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease","volume":"163","author":"Tzourio","year":"2003","journal-title":"Arch Intern Med"},{"key":"2025052516462920200_ref10","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1001\/jama.2018.21442","article-title":"Effect of intensive vs standard blood pressure control on probable dementia: A randomized clinical trial","volume":"321","author":"Williamson","year":"2019","journal-title":"JAMA"},{"key":"2025052516462920200_ref11","first-page":"Cd004034","article-title":"The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease","author":"McGuinness","year":"2006","journal-title":"Cochrane Database Syst Rev"},{"key":"2025052516462920200_ref12","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s40263-015-0230-6","article-title":"Antihypertensive drugs, prevention of cognitive decline and dementia: A systematic review of observational studies, randomized controlled trials and meta-analyses, with discussion of potential mechanisms","volume":"29","author":"Rouch","year":"2015","journal-title":"CNS Drugs"},{"key":"2025052516462920200_ref13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.14283\/jpad.2022.77","article-title":"Antihypertensive agents and incident Alzheimer's disease: A systematic review and meta-analysis of observational studies","volume":"9","author":"Adesuyan","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"2025052516462920200_ref14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1474-4422(19)30393-X","article-title":"Antihypertensive medications and risk for incident dementia and Alzheimer's disease: A meta-analysis of individual participant data from prospective cohort studies","volume":"19","author":"Ding","year":"2020","journal-title":"Lancet Neurol"},{"key":"2025052516462920200_ref15","doi-asserted-by":"publisher","first-page":"4980","DOI":"10.1093\/eurheartj\/ehac584","article-title":"Blood pressure lowering and prevention of dementia: An individual patient data meta-analysis","volume":"43","author":"Peters","year":"2022","journal-title":"Eur Heart J"},{"key":"2025052516462920200_ref16","doi-asserted-by":"publisher","first-page":"105515","DOI":"10.1016\/j.phrs.2021.105515","article-title":"Association between renin-angiotensin-aldosterone system inhibitors and risk of dementia: A meta-analysis","volume":"166","author":"Scotti","year":"2021","journal-title":"Pharmacol Res"},{"key":"2025052516462920200_ref17","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/bcp.12511","article-title":"Angiotensin receptor blockers and risk of dementia: Cohort study in UK clinical practice research datalink","volume":"79","author":"Goh","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2025052516462920200_ref18","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3233\/JAD-190362","article-title":"The relationship between the use of antihypertensive drugs and the incidence of dementia in general practices in Germany","volume":"70","author":"Bohlken","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2025052516462920200_ref19","doi-asserted-by":"publisher","first-page":"e0206705","DOI":"10.1371\/journal.pone.0206705","article-title":"The association of multiple anti-hypertensive medication classes with Alzheimer's disease incidence across sex, race, and ethnicity","volume":"13","author":"Barthold","year":"2018","journal-title":"PLoS One"},{"key":"2025052516462920200_ref20","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.3233\/JAD-180943","article-title":"Observational study of brain atrophy and cognitive decline comparing a sample of community-dwelling people taking angiotensin converting enzyme inhibitors and angiotensin receptor blockers over time","volume":"68","author":"Moran","year":"2019","journal-title":"J Alzheimers Dis"},{"key":"2025052516462920200_ref21","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/gerona\/60.1.67","article-title":"Cross-sectional and longitudinal association between antihypertensive medications and cognitive impairment in an elderly population","volume":"60","author":"Hajjar","year":"2005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2025052516462920200_ref22","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.3233\/JAD-171119","article-title":"The coming of age of the angiotensin hypothesis in Alzheimer's disease: Progress toward disease prevention and treatment?","volume":"62","author":"Kehoe","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2025052516462920200_ref23","doi-asserted-by":"publisher","first-page":"37644","DOI":"10.1074\/jbc.M508460200","article-title":"Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor","volume":"280","author":"Hemming","year":"2005","journal-title":"J Biol Chem"},{"key":"2025052516462920200_ref24","doi-asserted-by":"publisher","first-page":"47863","DOI":"10.1074\/jbc.M104068200","article-title":"Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity","volume":"276","author":"Hu","year":"2001","journal-title":"J Biol Chem"},{"key":"2025052516462920200_ref25","doi-asserted-by":"publisher","first-page":"3894","DOI":"10.1002\/alz.13062","article-title":"Evaluating the association between genetically proxied ACE inhibition and dementias","volume":"19","author":"Nassan","year":"2023","journal-title":"Alzheimers Dement"},{"key":"2025052516462920200_ref26","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1093\/ije\/dyz155","article-title":"Repurposing antihypertensive drugs for the prevention of Alzheimer's disease: A Mendelian randomization study","volume":"49","author":"Walker","year":"2020","journal-title":"Int J Epidemiol"},{"key":"2025052516462920200_ref27","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S2215-0366(18)30293-1","article-title":"Trends in attention-deficit hyperactivity disorder medication use: A retrospective observational study using population-based databases","volume":"5","author":"Raman","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"2025052516462920200_ref28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/S2215-0366(23)00332-2","article-title":"ADHD medication discontinuation and persistence across the lifespan: A retrospective observational study using population-based databases","volume":"11","author":"Brikell","year":"2024","journal-title":"Lancet Psychiatry"},{"key":"2025052516462920200_ref29","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afad014","article-title":"Trends of polypharmacy among older people in Asia, Australia and the United Kingdom: A multinational population-based study","volume":"52","author":"Lee","year":"2023","journal-title":"Age Ageing"},{"key":"2025052516462920200_ref30","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1001\/jama.2017.1363","article-title":"Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with Nonvalvular atrial fibrillation","volume":"317","author":"Lau","year":"2017","journal-title":"JAMA"},{"key":"2025052516462920200_ref31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/pds.1335","article-title":"Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research","volume":"16","author":"Lewis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2025052516462920200_ref32","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"key":"2025052516462920200_ref33","doi-asserted-by":"publisher","first-page":"e021122","DOI":"10.1136\/bmjopen-2017-021122","article-title":"The validity of the Rx-risk comorbidity index using medicines mapped to the anatomical therapeutic chemical (ATC) classification system","volume":"8","author":"Pratt","year":"2018","journal-title":"BMJ Open"},{"key":"2025052516462920200_ref34","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: Historical foundations and contemporary application","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"key":"2025052516462920200_ref35","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"2025052516462920200_ref36","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1002\/ijc.34846","article-title":"Healthy lifestyle and cancer survival: A multinational cohort study","volume":"154","author":"Bian","year":"2024","journal-title":"Int J Cancer"},{"key":"2025052516462920200_ref37","volume-title":"Hypertension in Adults: Diagnosis and Management","author":"National Institute for Health and Care Excellence (NICE)"},{"key":"2025052516462920200_ref38","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1161\/01.CIR.97.14.1411","article-title":"Angiotensin-converting enzyme inhibitors","volume":"97","author":"Brown","year":"1998","journal-title":"Circulation"},{"key":"2025052516462920200_ref39","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.amjhyper.2004.11.032","article-title":"Mechanisms for the clinical benefits of angiotensin II receptor blockers","volume":"18","author":"Schmieder","year":"2005","journal-title":"Am J Hypertens"},{"key":"2025052516462920200_ref40","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1476-5381.2010.01167.x","article-title":"Role of angiotensin II receptor subtype activation in cognitive function and ischaemic brain damage","volume":"163","author":"Horiuchi","year":"2011","journal-title":"Br J Pharmacol"},{"key":"2025052516462920200_ref41","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.sjbs.2020.01.026","article-title":"Role of brain renin angiotensin system in neurodegeneration: An update","volume":"27","author":"Abiodun","year":"2020","journal-title":"Saudi J Biol Sci"},{"key":"2025052516462920200_ref42","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1097\/00001756-199208000-00013","article-title":"Angiotensin AT2 receptors regulate cerebral blood flow in rats","volume":"3","author":"Str\u00f6mberg","year":"1992","journal-title":"Neuroreport"},{"key":"2025052516462920200_ref43","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.psc.2022.07.011","article-title":"Epidemiology and risk factors for dementia","volume":"45","author":"Dintica","year":"2022","journal-title":"Psychiatr Clin North Am"},{"key":"2025052516462920200_ref44","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/brain\/awac076","article-title":"Blood-brain barrier permeable \u03b2-blockers linked to lower risk of Alzheimer's disease in hypertension","volume":"146","author":"Beaman","year":"2023","journal-title":"Brain"},{"key":"2025052516462920200_ref45","doi-asserted-by":"publisher","first-page":"106649","DOI":"10.1016\/j.vph.2020.106649","article-title":"Beta-blocker therapy and risk of vascular dementia: A population-based prospective study","volume":"125-126","author":"Holm","year":"2020","journal-title":"Vasc Pharmacol"},{"key":"2025052516462920200_ref46","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2165\/00002512-199303030-00005","article-title":"Age-related changes in the renin-aldosterone system. Physiological effects and clinical implications","volume":"3","author":"Bauer","year":"1993","journal-title":"Drugs Aging"},{"key":"2025052516462920200_ref47","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1136\/bmj.38803.528113.55","article-title":"Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine","volume":"332","author":"McDowell","year":"2006","journal-title":"BMJ"},{"key":"2025052516462920200_ref48","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1212\/01.wnl.0000345062.86148.3f","article-title":"Duration of antihypertensive drug use and risk of dementia: A prospective cohort study","volume":"72","author":"Haag","year":"2009","journal-title":"Neurology"},{"key":"2025052516462920200_ref49","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1097\/01.wad.0000165511.52746.1f","article-title":"Association between dementia and infectious disease: Evidence from a case-control study","volume":"19","author":"Dunn","year":"2005","journal-title":"Alzheimer Dis Assoc Disord"},{"key":"2025052516462920200_ref50","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.3233\/JAD-170572","article-title":"Detection of dementia cases in two Swedish health registers: A validation study","volume":"61","author":"Rizzuto","year":"2018","journal-title":"J Alzheimers Dis"},{"key":"2025052516462920200_ref51","doi-asserted-by":"publisher","first-page":"h6926","DOI":"10.1136\/bmj.h6926","article-title":"Cardiovascular outcomes associated with use of clarithromycin: Population based study","volume":"352","author":"Wong","year":"2016","journal-title":"BMJ (Clinical Research Ed)"}],"container-title":["Age and Ageing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/54\/5\/afaf121\/63349511\/afaf121.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ageing\/article-pdf\/54\/5\/afaf121\/63349511\/afaf121.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T16:46:37Z","timestamp":1748191597000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ageing\/article\/doi\/10.1093\/ageing\/afaf121\/8148675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ageing\/afaf121","relation":{},"ISSN":["0002-0729","1468-2834"],"issn-type":[{"value":"0002-0729","type":"print"},{"value":"1468-2834","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"afaf121"}}